West Pharmaceutical Services WST Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Proprietary Products | $694.3M+23.3% | $661.8M+7.8% | $647.5M+7.7% | $619.8M+10.7% | $563M+0.6% | |
| West Vantage | $150.6M+11.6% | —— | —— | —— | $135M— | |
| Other segment expense (income) by Business | ||||||
| Proprietary Products | $3.1M+3.3% | $6M-49.2% | $6.1M+13.0% | $6M+150% | $3M+20.0% | |
| West Vantage | -$100K-117% | —— | —— | —— | $600K— | |
| Total Assets by Business | ||||||
| Proprietary Products | $2.93B+11.7% | $2.99B+14.0% | $2.99B— | $2.83B— | $2.63B— | |
| West Vantage | $739.6M— | $718.1M— | —— | —— | —— | |
| Operating Income (Loss) by Business | ||||||
| Proprietary Products | $189.2M+44.9% | $189.7M+16.9% | $175.2M+10.7% | $161.7M+23.4% | $130.6M+3.4% | |
| West Vantage | $15.6M+15.6% | —— | —— | —— | $13.5M— | |
| Selling, general and administrative expenses by Business | ||||||
| Proprietary Products | $65M+7.8% | $68.2M+17.4% | $65.6M+15.9% | $61.5M+9.6% | $60.3M-0.7% | |
| West Vantage | $7.8M+2.6% | —— | —— | —— | $7.6M— | |
| Cost of goods and services sold by Business | ||||||
| Proprietary Products | $421.2M+19.4% | $376.1M+3.6% | $383.5M+4.9% | $371.5M+5.3% | $352.8M+0.1% | |
| West Vantage | $127.3M+12.4% | —— | —— | —— | $113.3M— | |
| Capital Expenditures by Business | ||||||
| Proprietary Products | $36.5M-29.7% | $56.2M-29.0% | $47.7M-0.2% | $48.5M-17.1% | $51.9M-15.1% | |
| West Vantage | $5.6M-69.1% | —— | —— | —— | $18.1M— | |
| R&D by Business | ||||||
| Proprietary Products | $15.8M-3.1% | $21.8M+17.8% | $17.1M+10.3% | $19.1M+9.1% | $16.3M-7.4% | |
| West Vantage | $0— | —— | —— | —— | $0— | |
| Depreciation and Amortization by Business | ||||||
| Proprietary Products | $36.4M+11.3% | $38.7M+15.5% | $35.1M+3.8% | $33.7M+2.1% | $32.7M+9.0% | |
| West Vantage | $8M+25.0% | —— | —— | —— | $6.4M— | |
| Concentration risk, percentage by Product | ||||||
| High-Value Product ("HVP") Components | 48%+3.0pp | —— | 48%+3.0pp | 47%+1.0pp | 45%-2.0pp | |
| High-Value Product ("HVP") Delivery Devices | 15%+1.0pp | —— | —— | —— | 14%— | |
| Standard Packaging | 19%-3.0pp | 8%-2.0pp | 12%-4.0pp | 13%+2.0pp | 22%+11.0pp | |
| West Vantage | 18%-1.0pp | —— | —— | —— | 19%— | |
| Concentration risk, percentage by Geography | ||||||
| Americas | 45%-4.0pp | —— | 47%-1.0pp | 45%+2.0pp | 49%+6.0pp | |
| Asia Pacific | 8%+1.0pp | 1%— | 8%0.0pp | 9%0.0pp | 7%-2.0pp | |
| Europe, Middle East, Africa | 47%+3.0pp | —— | 45%+1.0pp | 46%-2.0pp | 44%-4.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does West Pharmaceutical Services break its business down?
- West Pharmaceutical Services (WST) reports net sales by business across 2 parts — Proprietary Products and West Vantage. Each is extracted from the segment footnotes and tracked over time.
- Where does West Pharmaceutical Services's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in West Pharmaceutical Services's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
